Lupin and DKSH have signed an exclusive license and supply agreement to commercialize five of Alvotechs proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia, Xgeva, Simponi, and Eylea as well as two undisclosed proposed biosimilars for immunology and oncology.
- Read more about Lupin and DKSH inks to market five biosimilar candidates in Philippines
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/lupin-and-dksh-inks-market-five-biosimilar-candidates-in-philippines
No comments:
Post a Comment